Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Lenalidomide in Relapsed/Refractory Hodgkin's Lymphoma
NCT01460940Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2011
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat, lenalidomide in Hodgkin lymphoma (HL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Oct 2011; status: completed.
02
Drugs
panobinostatlenalidomide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01460940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01460940.